Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 185

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 185
---
 of the Merger Agreement and not by this description, which is summary by nature, or by any other description of the Merger Agreement in this Proxy Statement/Prospectus. This description does not purport to be complete, may not contain all of the information about the Merger Agreement that is important to you and is qualified in its entirety by reference to the complete text of the Merger Agreement. You are encouraged to read the Merger Agreement carefully and in its entirety, as well as this Proxy Statement/Prospectus, before making any decisions regarding any of the proposals described in this Proxy Statement/Prospectus.

Explanatory Note Regarding the Merger Agreement

The following description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full
text of the Merger Agreement, which is included as Annex A attached hereto. The Merger Agreement has been included to provide Enfusion Stockholders with information regarding its terms. It is not intended to provide any other factual
information about Enfusion, Enfusion OpCo, Clearwater, Acquirer, Merger Sub, Merger Sub II or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of
the Merger Agreement as of the specific dates therein, were solely for the benefit of the parties to the Merger Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures
made for the purposes of allocating contractual risk among the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from
those applicable to Enfusion Stockholders. Enfusion Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or
any of their respective subsidiaries or affiliates. Moreover, the covenants may be waived or subject to exceptions and information concerning the subject matter of representations and warranties may change after the date of the Merger Agreement,
which waivers, exceptions and subsequent information may or may not be reflected in Enfusion’s public disclosures. Accordingly, the representations, warranties, covenants and other agreements in the Merger Agreement should not be read alone,
and you should read the information provided elsewhere in this document and in our filings with the SEC regarding Enfusion and its business. See the section of this Proxy Statement/